AVIR - CIK 0001593899
Atea Pharmaceuticals, Inc. trades as AVIR. This page tracks Atea Pharmaceuticals, Inc. through 301 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade (amended) | 4/A | 2026-05-21 |
| Insider trade | 4 | 2026-05-20 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
| SCHEDULE 13G/A | - | 2026-03-26 |
The largest companies sharing Atea Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Atea Pharmaceuticals, Inc. reported a net loss of $158.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.